Target intelligence / Profile preview

Tumor necrosis factor receptor superfamily member 11A (RANK)

Target
RANK
Molecular classification
Receptor
01

Overview

Tumor necrosis factor receptor superfamily member 11A (TNFRSF11A), commonly known as Receptor Activator of Nuclear Factor-κB (RANK), is a type I transmembrane protein that plays a pivotal role in bone homeostasis and immune regulation. Upon binding to its cognate ligand, RANKL (TNFSF11), RANK recruits tumor necrosis factor receptor-associated factors (TRAFs) to activate downstream signaling cascades, including the NF-κB, MAPK, and JNK pathways. This signaling axis is the master regulator of osteoclastogenesis, driving the differentiation, activation, and survival of bone-resorbing osteoclasts. Beyond bone remodeling, RANK signaling is involved in T-cell and dendritic cell interactions, lymph node organogenesis, and mammary gland development.

Dysregulation of the RANK/RANKL pathway is implicated in various bone pathologies and malignancies. Overactivation of this pathway leads to excessive bone resorption, contributing to osteoporosis, Paget's disease of bone, and osteolytic bone metastases in cancers such as breast and prostate cancer. Conversely, loss-of-function mutations in TNFRSF11A cause osteoclast-poor autosomal recessive osteopetrosis. In oncology, RANK expression on tumor cells promotes epithelial-mesenchymal transition, migration, and the establishment of a metastatic niche in bone. Therapeutic targeting of this pathway is clinically achieved using denosumab, a monoclonal antibody that binds RANKL to prevent its interaction with RANK, thereby effectively suppressing osteoclast-mediated bone destruction.

Other names
TNFRSF11ACD265Receptor activator of NF-KBOsteoclast differentiation factor receptorODFRTRANCE receptorTRANCE-RFEOLOH18CR1PDB2
02

Mechanism of action

Inhibition of the RANKL/RANK signaling pathway. Denosumab is a monoclonal antibody that binds to RANKL (the ligand of RANK), preventing it from binding to and activating the RANK receptor on osteoclast precursors and mature osteoclasts. This blocks downstream NF-κB and MAPK signaling, thereby suppressing osteoclast differentiation, activation, and survival, and reducing bone resorption.

03

Biological functions

Signal transductionImmune responseCell differentiationOther
04

Disease associations

CancerInflammationOther
05

Safety considerations

HypocalcemiaOsteonecrosis of the jaw (ONJ)Atypical femoral fractures (AFF)Rebound hypercalcemia and rapid bone loss upon drug discontinuationIncreased risk of infectionSkin reactions
06

Interacting drugs

1 more in the full profile.

07

Biomarkers

C-terminal telopeptide of type 1 collagen (CTX)N-terminal telopeptide of type 1 collagen (NTX)Bone-specific alkaline phosphatase (BSAP)Procollagen type 1 N-propeptide (P1NP)Serum calciumParathyroid hormone (PTH)RANK expressionRANKL expression

Beyond the preview

Go deeper on Tumor necrosis factor receptor superfamily member 11A (RANK).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tumor necrosis factor receptor superfamily member 11A (RANK).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call